España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Intra-Cellular Therapies
ITCI
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$127.15
0.65
0.51%
At close: -
$127.56
0.41
0.32%
After Hours: 4:10 PM EDT
Get Report
Comment
Intra-Cellular Therapies (ITCI) Forecast
News
Earnings
Intra-Cellular Therapies (ITCI) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Intra-Cellular Therapies (NASDAQ:ITCI) Stock
Intra-Cellular Therapies Stock (NASDAQ: ITCI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 22, 2025
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
Benzinga Insights
RBC Capital Downgrades Intra-Cellular Therapi...
Benzinga Newsdesk
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Vandana Singh
Tuesday, January 21, 2025
Top 4 Health Care Stocks You May Want To Dump In Q1
Avi Kapoor
Sunday, January 19, 2025
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Lekha Gupta
Tuesday, January 14, 2025
Piper Sandler Downgrades Intra-Cellular Thera...
Benzinga Newsdesk
Monday, January 13, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Vaishali Prayag
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Avi Kapoor
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Avi Kapoor
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Needham Downgrades Intra-Cellular Therapies t...
Benzinga Newsdesk
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Vandana Singh
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Johnson & Johnson Says Intra-Cellular Acquisi...
Benzinga Newsdesk
Intra-Cellular Therapies shares are trading h...
Benzinga Newsdesk
Johnson & Johnson Agrees To Acquire Intra-cel...
Benzinga Newsdesk
Johnson & Johnson Has Agreed To Acquire Intra...
Benzinga Newsdesk
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Sunday, January 12, 2025
Bloomberg Reported Sunday, J&J Explores Bid F...
Benzinga Newsdesk
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Lekha Gupta
Friday, January 10, 2025
Intra-Cellular Therapies Enters Settlement Ag...
Benzinga Newsdesk
Intra-cellular Therapies Says It Has Entered ...
Benzinga Newsdesk
Tuesday, December 31, 2024
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Vandana Singh
Wednesday, December 11, 2024
Intra-Cellular Therapies Presents Data From T...
Benzinga Newsdesk
Tuesday, December 03, 2024
Intra-Cellular Therapies Submitted A Suppleme...
Benzinga Newsdesk
Tuesday, November 05, 2024
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Vandana Singh
Intra-Cellular Therapies Reports Results From...
Benzinga Newsdesk
Monday, November 04, 2024
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
Benzinga Insights
JP Morgan Maintains Overweight on Intra-Cellu...
Benzinga Newsdesk
Thursday, October 31, 2024
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
Wednesday, October 30, 2024
Intra-Cellular Therapies shares are trading h...
Benzinga Newsdesk
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
CAPLYTA Raised 2024 Net Product Sales Guidanc...
Benzinga Newsdesk
Intra-Cellular Therapies Q3 2024 GAAP EPS $(0...
Benzinga Newsdesk
Tuesday, October 29, 2024
Earnings Preview For Intra-Cellular Therapies
Benzinga Insights
Friday, October 11, 2024
Morgan Stanley Maintains Overweight on Intra-...
Benzinga Newsdesk
Friday, October 04, 2024
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
Benzinga Insights
RBC Capital Maintains Outperform on Intra-Cel...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Friday, September 06, 2024
Expert Ratings For Intra-Cellular Therapies
Benzinga Insights
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Avi Kapoor
Piper Sandler Upgrades Intra-Cellular Therapi...
Benzinga Newsdesk
Wednesday, August 21, 2024
JP Morgan Maintains Overweight on Intra-Cellu...
Benzinga Newsdesk
Thursday, August 08, 2024
RBC Capital Maintains Outperform on Intra-Cel...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Int...
Benzinga Newsdesk
UBS Maintains Neutral on Intra-Cellular Thera...
Benzinga Newsdesk
Goldman Sachs Maintains Neutral on Intra-Cell...
Benzinga Newsdesk
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch